Home
Mobile version
spiked plus
About spiked
What is spiked?
Support spiked
spiked shop
Contact us
Advertising
Summer school
Top issues
Abortion
Arab uprisings
British politics
Child abuse panic
Economy
Environment
For Europe, Against the EU
Free speech
Jimmy Savile scandal
Nudge
Obesity
Parents and kids
Population
USA
View all issues...
special feature
The Counter-Leveson Inquiry
other sections
 Letters
 Review of Books
 Monthly archive
selected authors
Duleep Allirajah
Daniel Ben-Ami
Tim Black
Jennie Bristow
Sean Collins
Dr Michael Fitzpatrick
Frank Furedi
Helene Guldberg
Patrick Hayes
Mick Hume
Rob Lyons
Brendan O’Neill
Nathalie Rothschild
James Woudhuysen
more authors...
RSS feed
survey

abc def ghi jkl mno pqrs tuv wxyz index
Survey home
Introduction
Survey responses
RSS feed
Anjana Ahuja
Julian Baggini
Philip Ball
Marlene Oscar Berman
Gustav VR Born
K Eric Drexler
Marcus Du Sautoy
Edmond H Fischer
John Hall
Tim Hunt
Wolfgang Ketterle
Leon Lederman
Matt Ridley
Raymond Tallis
Frank Wilczek
Lewis Wolpert
Michael Baum
emeritus professor of surgery and visiting professor of medical humanities at University College London.


I have spent most of my academic career studying the diagnosis and treatment of breast cancer. I have no doubt about the most important innovation in my field over the last 200 years. It was not a surgical technique, it was not the discovery of radiotherapy or a new drug but a paradigm shift about the nature of the disease. Until the late 1970s breast cancer was considered as an anatomical challenge to be defeated by the skills of the surgeon alone until a group of revolutionaries, lead by Dr. Bernard Fisher of Pittsburgh PA, described an alternative model that better explained some enigmatic features of the disease.

We now accept that in the majority of cases we are dealing with a systemic disorder with the primary tumour as the tip of an iceberg. The therapeutic consequences of this conceptual revolution have been better survival following the early exhibition of chemotherapy regimens and tamoxifen, together with less mutilating surgery combined with modern radiotherapeutic techniques, that have preserved the breast and improved quality of life for the survivors.

Since 1980, mortality from breast cancer has fallen by more than 30 per cent in the UK alone as a result of the new technologies being harnessed to a new conceptual framework.

Michael Baum is emeritus professor of surgery and visiting professor of medical humanities at University College London, chair of the Psychosocial Oncology Committee at the National Cancer Research Institute and editor-in-chief of the International Journal of Surgery.